Found 19 matching trials
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study PHASE2 This is a prospective, multicenter, open-label, randomized, controlled Stud...
Show More Location
Multiple Locations
Learn More & Join Trial
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis PHASE1 In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR...
Show More Location
Fudan Cancer Hospital
Learn More & Join Trial
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy PHASE2 The purpose of this study is to establish a prospective, single-center plat...
Show More Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Learn More & Join Trial
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy PHASE3 Based on total pathologic complete response (tpCR) after surgery, to evalua...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer PHASE2 Patients with Stage II-III HER2-positive breast cancer will receive three c...
Show More Location
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
Learn More & Join Trial
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer PHASE2 This prospective, response-guided phase II study investigates individualize...
Show More Location
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Learn More & Join Trial
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study PHASE2 Breast cancer is the most common malignancy in women, with approximately 20...
Show More Location
Multiple Locations
Learn More & Join Trial
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer PHASE1 This study was an open, multicenter, dose-increasing/investigational Phase ...
Show More Location
Shanghai Chest hospital
Learn More & Join Trial
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP PHASE4 This is a prospective, multi-center, single-arm, phase 2 exploratory study ...
Show More Location
Multiple Locations
Learn More & Join Trial
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer PHASE2 The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrot...
Show More Location
Multiple Locations
Learn More & Join Trial